Oticon Medical announced clearance of its first active transcutaneous bone conduction hearing system, the Sentio System.
The Sentio System offers the established advantages than the Ponto™ System, additional benefits, in a transcutaneous format.
Unlike PontoTM and other percutaneous bone-anchored hearing systems that use supports protruding through the skin, the Sentio System offers an option that preserves the integrity of the skin.
The system features the Sentio 1 Mini, a compact external sound processor, paired with the Sentio Ti Implant, which is positioned beneath the skin. It is currently the smallest available transcutaneous system in the market.
Sentio System, will provide best-in-class and the smallest active transcutaneous system. More importantly, Oticon Medical now offers a complete collection of bone-anchored hearing systems.
The Sentio 1 Mini is designed to meet the needs of both patients and customers, providing various clinical settings and aligning with global reimbursement models for treatment.
With its user-centric design, the device not only enhances quality of life but also increases accessibility, benefiting a larger number of people. Its elegant profile makes it 26% lighter compared to similar alternatives, prioritizing user comfort and ease of use.
Moreover, the device delivers a 360-degree sound experience and boasts an impressive bandwidth of 9.5 kHz, ensuring superior auditory performance.
The Sentio Ti is designed and tested for a higher maximum force output, ensuring it can support more advanced sound processors.
The Sentio System is intended for individuals aged 12 and above who are diagnosed with conductive hearing loss, mixed hearing loss, or single-sided deafness.
Sentio Ti offers cutting-edge hearing solutions, empowering individuals to live life to the fullest.
Source: https://www.businesswire.com/news/home/20240712765107/en/Oticon-Medical%E2%80%99s-Sentio%E2%84%A2-System-Receives-Regulatory-Clearance-in-the-US
